Solomon Moshkevich Sells 1,652 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,652 shares of Natera stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $202.84, for a total transaction of $335,091.68. Following the completion of the sale, the insider owned 140,643 shares in the company, valued at approximately $28,528,026.12. This trade represents a 1.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The stock was sold at an average price of $204.10, for a total transaction of $445,346.20.
• On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $202.30, for a total transaction of $606,900.00.
• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total transaction of $186,778.95.
• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $199.85, for a total transaction of $599,550.00.

Natera Trading Up 4.4%

NTRA opened at $223.37 on Friday. The firm has a market capitalization of $31.99 billion, a PE ratio of -137.04 and a beta of 1.57. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The firm’s 50-day moving average price is $202.37 and its 200 day moving average price is $215.69.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The firm had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.05% and a negative return on equity of 14.74%. During the same period in the previous year, the business posted ($0.41) earnings per share. As a group, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent research reports. Morgan Stanley lowered their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Evercore restated an “outperform” rating and set a $270.00 price target on shares of Natera in a research report on Friday, May 8th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Finally, William Blair began coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $256.60.

Institutional Trading of Natera

Several hedge funds have recently made changes to their positions in the company. Coatue Management LLC grew its holdings in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the period. Wellington Management Group LLP grew its holdings in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the period. Norges Bank purchased a new position in shares of Natera during the 4th quarter worth $372,398,000. JPMorgan Chase & Co. raised its stake in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares during the period. Finally, Franklin Resources Inc. raised its stake in shares of Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.